Implementing the WHO Labour Care Guide to reduce the use of Caesarean section in four hospitals in India: protocol and statistical analysis plan for a pragmatic, stepped-wedge, cluster-randomized pilot trial.


Journal

Reproductive health
ISSN: 1742-4755
Titre abrégé: Reprod Health
Pays: England
ID NLM: 101224380

Informations de publication

Date de publication:
20 Jan 2023
Historique:
received: 25 04 2022
accepted: 08 11 2022
entrez: 20 1 2023
pubmed: 21 1 2023
medline: 25 1 2023
Statut: epublish

Résumé

The World Health Organization (WHO) Labour Care Guide (LCG) is a paper-based labour monitoring tool designed to facilitate the implementation of WHO's latest guidelines for effective, respectful care during labour and childbirth. Implementing the LCG into routine intrapartum care requires a strategy that improves healthcare provider practices during labour and childbirth. Such a strategy might optimize the use of Caesarean section (CS), along with potential benefits on the use of other obstetric interventions, maternal and perinatal health outcomes, and women's experience of care. However, the effects of a strategy to implement the LCG have not been evaluated in a randomised trial. This study aims to: (1) develop and optimise a strategy for implementing the LCG (formative phase); and (2) To evaluate the implementation of the LCG strategy compared with usual care (trial phase). In the formative phase, we will co-design the LCG strategy with key stakeholders informed by facility assessments and provider surveys, which will be field tested in one hospital. The LCG strategy includes a LCG training program, ongoing supportive supervision from senior clinical staff, and audit and feedback using the Robson Classification. We will then conduct a stepped-wedge, cluster-randomized pilot trial in four public hospitals in India, to evaluate the effect of the LCG strategy intervention compared to usual care (simplified WHO partograph). The primary outcome is the CS rate in nulliparous women with singleton, term, cephalic pregnancies in spontaneous labour (Robson Group 1). Secondary outcomes include clinical and process of care outcomes, as well as women's experience of care outcomes. We will also conduct a process evaluation during the trial, using standardized facility assessments, in-depth interviews and surveys with providers, audits of completed LCGs, labour ward observations and document reviews. An economic evaluation will consider implementation costs and cost-effectiveness. Findings of this trial will guide clinicians, administrators and policymakers on how to effectively implement the LCG, and what (if any) effects the LCG strategy has on process of care, health and experience outcomes. The trial findings will inform the rollout of LCG internationally. CTRI/2021/01/030695 (Protocol version 1.4, 25 April 2022). The new WHO Labour Care Guide (LCG) is an innovative partograph that emphasises women-centred, evidence-based care during labour and childbirth. Together with clinicians working at four hospitals in India, we will develop and test a strategy to implement the LCG into routine care in labour wards of these hospitals. We will use a randomised trial design where this LCG strategy is introduced sequentially in each of the four hospitals, in a random order. We will collect data on all women giving birth and their newborns during this period and analyse whether the LCG strategy has any effects on the use of Caesarean section, women’s and newborn’s health outcomes, and women’s experiences during labour and childbirth. While the trial is being conducted, we will also collect qualitative and quantitative data from doctors, nurses and midwives working in these hospitals, to understand their perspectives and experiences of using the LCG in their day-to-day work. In addition, we will collect economic data to understand how much the LCG strategy costs, and how much money it might save if it is effective. Through this study, our international collaboration will generate critical evidence and innovative tools to support implementation of the LCG in other countries.

Sections du résumé

BACKGROUND BACKGROUND
The World Health Organization (WHO) Labour Care Guide (LCG) is a paper-based labour monitoring tool designed to facilitate the implementation of WHO's latest guidelines for effective, respectful care during labour and childbirth. Implementing the LCG into routine intrapartum care requires a strategy that improves healthcare provider practices during labour and childbirth. Such a strategy might optimize the use of Caesarean section (CS), along with potential benefits on the use of other obstetric interventions, maternal and perinatal health outcomes, and women's experience of care. However, the effects of a strategy to implement the LCG have not been evaluated in a randomised trial. This study aims to: (1) develop and optimise a strategy for implementing the LCG (formative phase); and (2) To evaluate the implementation of the LCG strategy compared with usual care (trial phase).
METHODS METHODS
In the formative phase, we will co-design the LCG strategy with key stakeholders informed by facility assessments and provider surveys, which will be field tested in one hospital. The LCG strategy includes a LCG training program, ongoing supportive supervision from senior clinical staff, and audit and feedback using the Robson Classification. We will then conduct a stepped-wedge, cluster-randomized pilot trial in four public hospitals in India, to evaluate the effect of the LCG strategy intervention compared to usual care (simplified WHO partograph). The primary outcome is the CS rate in nulliparous women with singleton, term, cephalic pregnancies in spontaneous labour (Robson Group 1). Secondary outcomes include clinical and process of care outcomes, as well as women's experience of care outcomes. We will also conduct a process evaluation during the trial, using standardized facility assessments, in-depth interviews and surveys with providers, audits of completed LCGs, labour ward observations and document reviews. An economic evaluation will consider implementation costs and cost-effectiveness.
DISCUSSION CONCLUSIONS
Findings of this trial will guide clinicians, administrators and policymakers on how to effectively implement the LCG, and what (if any) effects the LCG strategy has on process of care, health and experience outcomes. The trial findings will inform the rollout of LCG internationally.
TRIAL REGISTRATION BACKGROUND
CTRI/2021/01/030695 (Protocol version 1.4, 25 April 2022).
The new WHO Labour Care Guide (LCG) is an innovative partograph that emphasises women-centred, evidence-based care during labour and childbirth. Together with clinicians working at four hospitals in India, we will develop and test a strategy to implement the LCG into routine care in labour wards of these hospitals. We will use a randomised trial design where this LCG strategy is introduced sequentially in each of the four hospitals, in a random order. We will collect data on all women giving birth and their newborns during this period and analyse whether the LCG strategy has any effects on the use of Caesarean section, women’s and newborn’s health outcomes, and women’s experiences during labour and childbirth. While the trial is being conducted, we will also collect qualitative and quantitative data from doctors, nurses and midwives working in these hospitals, to understand their perspectives and experiences of using the LCG in their day-to-day work. In addition, we will collect economic data to understand how much the LCG strategy costs, and how much money it might save if it is effective. Through this study, our international collaboration will generate critical evidence and innovative tools to support implementation of the LCG in other countries.

Autres résumés

Type: plain-language-summary (eng)
The new WHO Labour Care Guide (LCG) is an innovative partograph that emphasises women-centred, evidence-based care during labour and childbirth. Together with clinicians working at four hospitals in India, we will develop and test a strategy to implement the LCG into routine care in labour wards of these hospitals. We will use a randomised trial design where this LCG strategy is introduced sequentially in each of the four hospitals, in a random order. We will collect data on all women giving birth and their newborns during this period and analyse whether the LCG strategy has any effects on the use of Caesarean section, women’s and newborn’s health outcomes, and women’s experiences during labour and childbirth. While the trial is being conducted, we will also collect qualitative and quantitative data from doctors, nurses and midwives working in these hospitals, to understand their perspectives and experiences of using the LCG in their day-to-day work. In addition, we will collect economic data to understand how much the LCG strategy costs, and how much money it might save if it is effective. Through this study, our international collaboration will generate critical evidence and innovative tools to support implementation of the LCG in other countries.

Identifiants

pubmed: 36670438
doi: 10.1186/s12978-022-01525-4
pii: 10.1186/s12978-022-01525-4
pmc: PMC9862839
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

18

Informations de copyright

© 2023. The Author(s).

Références

Lancet Glob Health. 2019 May;7(5):e624-e632
pubmed: 30898495
Lancet Glob Health. 2015 May;3(5):e260-70
pubmed: 25866355
Stat Med. 2020 Sep 20;39(21):2779-2792
pubmed: 32578264
Birth. 2021 Mar;48(1):66-75
pubmed: 33225484
BMJ Glob Health. 2021 Jun;6(6):
pubmed: 34130991
Lancet. 2016 Oct 29;388(10056):2176-2192
pubmed: 27642019
BJOG. 2018 Jul;125(8):932-942
pubmed: 29117644
Rev Panam Salud Publica. 2015 Dec;38(6):506-14
pubmed: 27440100
BMC Pregnancy Childbirth. 2017 Jan 13;17(1):31
pubmed: 28086823
Biometrics. 2001 Mar;57(1):126-34
pubmed: 11252587
BJOG. 2021 Sep;128(10):1658-1662
pubmed: 33686760
Pilot Feasibility Stud. 2016 Oct 21;2:64
pubmed: 27965879
Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:123-132
pubmed: 29518643
Cochrane Database Syst Rev. 2012 Jun 13;(6):CD000259
pubmed: 22696318
BMJ. 2018 Nov 9;363:k1614
pubmed: 30413417
Cochrane Database Syst Rev. 2018 Aug 06;8:CD005461
pubmed: 30080256
BJOG. 2018 Jul;125(8):944-954
pubmed: 28892266
BMJ. 2013 May 09;346:f2838
pubmed: 23661113
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
PLoS Med. 2015 Jun 30;12(6):e1001847; discussion e1001847
pubmed: 26126110
BJOG. 2016 Apr;123(5):667-70
pubmed: 26681211
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Hum Resour Health. 2013 Oct 01;11:51
pubmed: 24083659

Auteurs

Joshua P Vogel (JP)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia. Joshua.vogel@burnet.edu.au.

Veronica Pingray (V)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Fernando Althabe (F)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Luz Gibbons (L)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Mabel Berrueta (M)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Yeshita Pujar (Y)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Manjunath Somannavar (M)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Sunil S Vernekar (SS)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Alvaro Ciganda (A)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Rocio Rodriguez (R)

Instituto de Efectividad Clínica y Sanitaria (IECS-CONICET), Buenos Aires, Argentina.

Saraswati A Welling (SA)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Amit Revankar (A)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Savitri Bendigeri (S)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Jayashree Ashok Kumar (JA)

Gadag Institute of Medical Sciences, Gadag, Karnataka, India.

Shruti Bhavi Patil (SB)

Gadag Institute of Medical Sciences, Gadag, Karnataka, India.

Aravind Karinagannanavar (A)

Gadag Institute of Medical Sciences, Gadag, Karnataka, India.

Raveendra R Anteen (RR)

General Hospital, Gokak, Belgaum, Karnataka, India.

M R Pavithra (MR)

General Hospital, Gokak, Belgaum, Karnataka, India.

Shukla Shetty (S)

JJM Medical College, Davangere, Karnataka, India.

B Latha (B)

JJM Medical College, Davangere, Karnataka, India.

H M Megha (HM)

JJM Medical College, Davangere, Karnataka, India.

Suman S Gaddi (SS)

Vijayanagar Institute of Medical Sciences (VIMS), Ballari, Karnataka, India.

Shaila Chikkagowdra (S)

Vijayanagar Institute of Medical Sciences (VIMS), Ballari, Karnataka, India.

Bellara Raghavendra (B)

Vijayanagar Institute of Medical Sciences (VIMS), Ballari, Karnataka, India.

Elizabeth Armari (E)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.

Nick Scott (N)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.

Katherine Eddy (K)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.

Caroline S E Homer (CSE)

Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.

Shivaprasad S Goudar (SS)

Women's and Children's Health Research Unit, Jawaharlal Nehru Medical College, KLE Academy of Higher Education and Research, Belgaum, Karnataka, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH